Evidence map›Paper›PMID 20543859›Full record

ReviewOncogene2010

The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation.

K M Crusio, B King, L B Reavie, I Aifantis

Abstract readReview
In one paragraph

Review in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Cancer, hear my battle CRY.Journal of pineal research · 2020
    Review
  15. Review
  16. Article
  17. FBW7 in hematological tumors.Oncology letters · 2020
    Review
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

K M CrusioHoward Hughes Medical Institute, Department of Pathology, NYU School of Medicine, New York, NY 10016, USA.
B King
L B Reavie
I Aifantis

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3M
The role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia.R01CA133379 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2009 to 2018
$3.6M
Regulation of hematopoietic stem cell differentiationR01CA105129 · NCI · UNIVERSITY OF CHICAGO · PI AIFANTIS, IANNIS · 2005 to 2014
$2.8M
Mechanisms of T cell leukemia induction and maintenanceR01CA149655 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2010 to 2015
$2.0M
Modifiers of Notch stability and their role in cancerR21CA141399 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, HUBBARD, E. JANE ALBERT · 2010 to 2011
$399k
NCI NIH HHS 5T32CA009161NCI NIH HHS P30 CA016087NCI NIH HHS P30CA016087NCI NIH HHS R01 CA105129NCI NIH HHS R01CA105129NCI NIH HHS R01 CA133379NCI NIH HHS R01CA133379NCI NIH HHS R01 CA149655NCI NIH HHS R01CA149655NCI NIH HHS R21 CA141399NCI NIH HHS R21CA141399NCI NIH HHS T32 CA009161
6 · The paper itself

Abstract

The ubiquitin-proteasome system (UPS) is a multi-subunit pathway that allows for ubiquitin modification of proteins and leads to either degradation or other non-proteolytic processes such as trafficking or transcriptional activation. Given its role as a regulator of cellular homeostasis it is not surprising that members of the UPS are frequently aberrantly expressed in a number of disease states including cancer. This review will focus on one member of the UPS, the F-box protein, Fbw7 (also known as Sel-10, Ago, hCDC4) and mechanisms by which Fbw7 interacts with its substrates in the context of development and tumorigenesis will be discussed. In addition, antagonists of this pathway as well as current and future therapeutics for the UPS will be examined.

Indexed as

Cell Transformation, NeoplasticAnimalsHumansNeoplasmsProto-Oncogene Proteins c-mybSKP Cullin F-Box Protein LigasesUbiquitinsProto-Oncogene Proteins c-mybSKP Cullin F-Box Protein LigasesUbiquitins

Identifiers

PMID20543859
PMCPMC3651593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.